摘要
目的探讨桂枝茯苓胶囊联合米非司酮对异位妊娠患者血清激素水平及炎性因子的影响,分析其可能作用机制。方法选择2015年2月至2016年2月收治的异位妊娠患者104例为研究对象,采用随机数字表法分为观察组和对照组各52例,对照组52例予以米非司酮和甲氨蝶呤治疗,观察组联合桂枝茯苓胶囊治疗,治疗3个月后,比较两组临床症状改善情况、血清激素水平、炎性因子、临床疗效等指标,同时选取50例正常孕妇为空白对照组。结果观察组有效率92.31%明显高于对照组75.00%(P<0.05);血清β-人绒毛膜促性腺激素(β-HCG)降至正常时间、腹痛消失时间、盆腔积血完全吸收时间均明显短于对照组(P<0.05);血清β-HCG、雌二醇(E2)、孕酮等激素水平均明显低于对照组(P<0.05);血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平均明显低于对照组(P<0.05)。结论桂枝茯苓胶囊联合米非司酮有助于改善异位妊娠患者临床症状,提高治疗效果,可能与降低血清激素水平、减少炎症因子释放等因素有关。
Objective To investigate the effect of Guizhi Fuling capsule combined with mifepristone on serum hormone and inflammatory factors levels of patients with ectopic pregnancy,and analyze the possible mechanism of action.Methods From February 2015 to February 2016,ectopic pregnancy treated 104 cases as the research object,randomly divided into observation group and control group with 52 cases in each group,the control group of 52 cases treated with mifepristone and methotrexate treatment,the observation group combined with Guizhifuling capsule.After 3 months of treatment,the clinical symptoms of two groups improved and serum hormone levels,inflammatory factors,clinical curative effect index,At the same time,50 normal pregnant women were selected as blank control group.Results The effective rate of observation group was92.31% significantly higher than the control group 75%(P0.05);serum beta human chorionic gonadotropin(β-HCG)to the normal time,the abdominal pain time,pelvic cavity accumulates blood completely absorbed time were significantly shorter than the control group(P0.05);serum beta-HCG,estradiol(E2)and progesterone(P)levels were significantly lower than the control group(P0.05);serum tumor necrosis factor alpha(TNF-alpha)and interleukin-8(IL-8)was significantly lower than that of control group(P0.05).Conclusion Guizhi Fuling Capsule Combined with mifepristone for ectopic pregnancy is helpful to improve clinical symptoms,improve the therapeutic effect,and may reduce the serum hormone level,reduce the release of inflammatory factors and other factors.
作者
王巧娥
胡小刚
肖发菊
WANG Qiaoe 1,HU Xiaogang 2,XIAO Faju 3(1.Department of Gynecology and Obstetrics,Maternal and Child Health Care Hospital of Xiaonan District,Xiaogan,Hubei 432100,China;2.Department of Orthopedics,Xiaogan First People′s Hospital,Xiaogan,Hubei 432100,China;3.Department of Obstetrics and Gynecology,the First People′s Hospital of Jingzhou Jingzhu,Hubei 434000,Chin)
出处
《国际检验医学杂志》
CAS
2018年第15期1813-1816,共4页
International Journal of Laboratory Medicine
基金
湖北省科学技术厅(EK111280)